摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(±)-(E)-1-(1-n-butylphthalazin-2(1H)-yl)-3-(5-((2,4-diaminopyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)prop-2-en-1-one

中文名称
——
中文别名
——
英文名称
(±)-(E)-1-(1-n-butylphthalazin-2(1H)-yl)-3-(5-((2,4-diaminopyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)prop-2-en-1-one
英文别名
(E)-(RS)-1-(1-Butyl-1H-phthalazin-2-yl)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-propenone;(E)-(RS)-3-[5-(2,4-diamino-pyrimidin-5-ylmethyl)-2,3-dimethoxy-phenyl]-1-(1-butyl-1H-phthalazin-2-yl)-propenone;1-(1-butylphthalazin-2(1H)-yl)-3-(5-((2,4-diaminopyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)prop-2-en-1-one;(E)-1-(1-butyl-1H-phthalazin-2-yl)-3-[5-[(2,4-diaminopyrimidin-5-yl)methyl]-2,3-dimethoxyphenyl]prop-2-en-1-one
(±)-(E)-1-(1-n-butylphthalazin-2(1H)-yl)-3-(5-((2,4-diaminopyrimidin-5-yl)methyl)-2,3-dimethoxyphenyl)prop-2-en-1-one化学式
CAS
——
化学式
C28H32N6O3
mdl
——
分子量
500.6
InChiKey
VMZJLCOUDXEVIH-VAWYXSNFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    37
  • 可旋转键数:
    9
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    129
  • 氢给体数:
    2
  • 氢受体数:
    8

反应信息

  • 作为产物:
    参考文献:
    名称:
    Synthesis and Biological Evaluation of 2,4-Diaminopyrimidine-Based Antifolate Drugs against Bacillus anthracis
    摘要:
    由于细菌天生具有对现有抗生素产生抗药性的能力,因此亟需开发新的药物来治疗抗药性更强的菌株。作为这一领域研究的延续,我们合成了一系列外消旋 2,4-二氨基嘧啶类候选药物,并对它们进行了抗炭疽杆菌的评估。这些药物的结构由一个 2,4-二氨基嘧啶环、一个 3,4-二甲氧基苄基环和一个 N-丙烯酰基取代的 1,2-二氢酞嗪环组成。对结构中二氢酞嗪分子的 C1 立体中心进行了各种改变,并通过测量 MIC 和 Ki 值来评估生物活性,以确定最有效的候选药物。
    DOI:
    10.3390/molecules19033231
点击查看最新优质反应信息

文献信息

  • Method for the treatment of anthrax infections
    申请人:Dreier Jurg
    公开号:US20100305119A1
    公开(公告)日:2010-12-02
    A method of treating an anthrax infection wherein a compound of formula I wherein R 1 and R 2 represent, independently of one another unsubstituted or specifically substituted C 1-4 alkoxy; and R 3 represents hydrogen; cyano; unsubstituted or specifically substituted C 1-6 alkyl; C 3-6 cycloalkyl; C 2-6 alkenyl; C 7-18 bicyclyl; aryl, aryl-C 1-4 alkyl, aryl-Q-C 1-4 alkyl heteroaryl, heterocyclyl or heterocyclyl-C 1-6 alkyl, wherein aryl denotes a mono- or poly-nucleous group with 6 to 14 ring carbon atoms; heterocyclyl denotes a 4- to 6-membered non-aromatic heterocyclic group comprising 1 to 3, nitrogen, oxygen and/or sulfur atoms; heteroaryl denotes a mono- or polynuclear heteroaromatic group consisting 5- and/or 6-membered rings and comprising 5 to 13 carbon atoms and 1 to 4, nitrogen, oxygen and/or sulfur atoms; and Q means —SO— or —SO 2 —; or a pharmaceutically acceptable salt, solvate or hydrate or a prodrug thereof; is administered to said subject in a quantity effective to inhibit, suppress, or expel an anthrax infection in said subject.
  • US8268825B2
    申请人:——
    公开号:US8268825B2
    公开(公告)日:2012-09-18
  • Synthesis and Biological Evaluation of 2,4-Diaminopyrimidine-Based Antifolate Drugs against Bacillus anthracis
    作者:Baskar Nammalwar、N. Muddala、Christina Bourne、Mary Henry、Philip Bourne、Richard Bunce、Esther Barrow、K. Berlin、William Barrow
    DOI:10.3390/molecules19033231
    日期:——
    Due to the innate ability of bacteria to develop resistance to available antibiotics, there is a critical need to develop new agents to treat more resilient strains. As a continuation of our research in this area, we have synthesized a series of racemic 2,4-diaminopyrimidine-based drug candidates, and evaluated them against Bacillus anthracis. The structures are comprised of a 2,4-diaminopyrimidine ring, a 3,4-dimethoxybenzyl ring, and an N-acryloyl-substituted 1,2-dihydrophthalazine ring. Various changes were made at the C1 stereocenter of the dihydrophthalazine moiety in the structure, and the biological activity was assessed by measurement of the MIC and Ki values to identify the most potent drug candidate.
    由于细菌天生具有对现有抗生素产生抗药性的能力,因此亟需开发新的药物来治疗抗药性更强的菌株。作为这一领域研究的延续,我们合成了一系列外消旋 2,4-二氨基嘧啶类候选药物,并对它们进行了抗炭疽杆菌的评估。这些药物的结构由一个 2,4-二氨基嘧啶环、一个 3,4-二甲氧基苄基环和一个 N-丙烯酰基取代的 1,2-二氢酞嗪环组成。对结构中二氢酞嗪分子的 C1 立体中心进行了各种改变,并通过测量 MIC 和 Ki 值来评估生物活性,以确定最有效的候选药物。
查看更多